Likar Rudolf, Koestenberger Markus, Stutschnig Martin, Nahler Gerhard
Abteilung für Anästhesiologie und Intensivmedizin, Klinikum Klagenfurt am Wörthersee,Klagenfurt am Wörthersee, Austria.
Medical University Graz, Graz, Austria.
Cancer Diagn Progn. 2021 May 3;1(2):77-82. doi: 10.21873/cdp.10011. eCollection 2021 May-Jun.
Glioblastoma multiforme (GBM) is a relatively rare type of brain tumour with an incidence rate around 6 per 100,000. Even with the widely practiced combination of radiotherapy with adjuvant temozolomide, the median overall survival remains low with just 13.5 to 16 months after diagnosis.
We retrospectively reviewed the survival of a cohort of 15 consecutive, unselected patients with histopathologically confirmed glioblastoma multiforme (GBM) who received CBD (400 to 600 mg orally per day) in addition to standard therapy (maximum resection of the tumour followed by radio-chemotherapy).
Of 15 patients, seven (46.7%) are now living for at least 24 months, and four (26.7%) for at least 36 months. This is more than twice as long as has been previously reported in the literature. The mean overall survival is currently 24.2 months (median 21 months).
CBD is a well supported co-medication and seems to prolong the survival of patients with glioblastoma multiforme.
多形性胶质母细胞瘤（GBM）是一种相对罕见的脑肿瘤，发病率约为每10万人中有6例。即使广泛采用放疗联合辅助替莫唑胺的治疗方法，诊断后的中位总生存期仍然很低，仅为13.5至16个月。
我们回顾性分析了一组连续的15例未经选择的组织病理学确诊为多形性胶质母细胞瘤（GBM）患者的生存情况，这些患者除接受标准治疗（肿瘤最大程度切除，随后进行放化疗）外，还接受了CBD（每天口服400至600毫克）治疗。
15例患者中，7例（46.7%）目前存活至少24个月，4例（26.7%）存活至少36个月。这比之前文献报道的生存期长两倍多。目前的平均总生存期为24.2个月（中位生存期为21个月）。
CBD是一种得到充分支持的辅助用药，似乎可以延长多形性胶质母细胞瘤患者的生存期。
